Osteonecrosis — also known as aseptic necrosis, ischemic bone disease, and avascular necrosis — is characterized by the death of bone tissue resulting from an inadequate blood supply. The disruption of blood flow causes structural breakdown within the affected bone. Recognized subtypes include avascular necrosis, osteonecrosis of genetic origin, osteochondrosis, osteoradionecrosis, Kummell disease, idiopathic phalangeal acro-osteolysis, and Dieterich disease, indicating that the condition encompasses a heterogeneous group of disorders with distinct etiologies. Sources include Orphanet (399158) and GARD (NIH).

Structured phenotype data are not present in the current packet for osteonecrosis. The breadth of recognized subtypes — ranging from radiation-associated forms to those of genetic origin — suggests that clinical presentation varies considerably depending on the affected subtype and anatomical site involved. No specific symptom profiles are recorded in the available data from Orphanet or GARD.

Osteonecrosis results from insufficient blood supply to bone tissue, as described in records from Orphanet and GARD. Recognized subtypes indicate that underlying causes may include genetic factors (osteonecrosis of genetic origin), ionizing radiation exposure (osteoradionecrosis), and idiopathic mechanisms. The packet contains no identified causative genes for the broader osteonecrosis category.

The current packet does not include structured diagnostic criteria or testing protocols for osteonecrosis. Diagnostic methods, imaging approaches, and clinical thresholds are not specified in the available Orphanet or GARD records for this entry.

No FDA-approved treatments are recorded in the packet for osteonecrosis. Three orphan drug designations have been granted by regulatory bodies: autologous adult live cultured osteoblasts (Regrow Biosciences), human allogeneic bone marrow-derived osteoblastic cells (Biosenic SA), and tissue repair cells derived from autologous bone marrow expanded ex vivo (Aastrom Biosciences). Orphan designation status reflects regulatory recognition of unmet medical need and does not indicate approved or available treatment. A fourth designation (Bone Therapeutics S.A.) has been withdrawn.

The packet does not contain structured prognosis or outcome data for osteonecrosis. Long-term course, functional outcomes, and prognostic factors are not described in the available Orphanet or GARD records for this condition.

Osteonecrosis is the subject of numerous active clinical investigations. ClinicalTrials.gov records 34 active studies as of the packet date, spanning drug therapy, procedural interventions, medical devices, and other intervention types. Ongoing work includes studies of mesenchymal stem cell-derived exosomes, hyperbaric oxygen therapy, bisphosphonates in sickle cell-associated osteonecrosis, and implant-related interventions. A published literature base of 184 classified articles is documented, with reviews and meta-analyses comprising the dominant publication type. Biomarker and gene therapy research publications are also present in the landscape, per the research digest.